A phase I, first-in-human study of MGD013 -What do we need to know about MGD013 - Jason Luke MD FACP - UPMC Hillman Cancer Center Immunology @jasonlukemd @UPMCHillmanCC @PittTweet #immuno...

A phase I, first-in-human study of MGD013 -What do we need to know about MGD013 - Jason Luke MD FACP - UPMC Hillman Cancer Center Immunology @jasonlukemd @UPMCHillmanCC @PittTweet #immuno...

User Photo
Cancer-News

1 month
15 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and the director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center Immunology and Immunotherapy Program discusses A phase I, first-in-human, open-label, dose-escalation study of MGD013.
Up Next Autoplay